Author: Rawal, Shruti; Patel, Mayur
Title: Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers Cord-id: aq7zcu2g Document date: 2021_6_12
ID: aq7zcu2g
Snippet: Lung cancer is a complex thoracic malignancy developing consequential to aberrations in a myriad of molecular and biomolecular signaling pathways. It is one of the most lethal forms of cancers accounting to almost 1.8 million new annual incidences, bearing overall mortality to incidence ratio of 0.87. The dismal prognostic scenario at advanced stages of the disease and metastatic/resistant tumor cell populations stresses the requisite of advanced translational interdisciplinary interventions suc
Document: Lung cancer is a complex thoracic malignancy developing consequential to aberrations in a myriad of molecular and biomolecular signaling pathways. It is one of the most lethal forms of cancers accounting to almost 1.8 million new annual incidences, bearing overall mortality to incidence ratio of 0.87. The dismal prognostic scenario at advanced stages of the disease and metastatic/resistant tumor cell populations stresses the requisite of advanced translational interdisciplinary interventions such as bionanotechnology. This review article deliberates insights and apprehensions on the recent prologue of nanobioengineering and bionanotechnology as an approach for the clinical management of lung cancer. The role of nanobioengineered (bio-nano) tools like bio-nanocarriers and nanobiodevices in secondary prophylaxis, diagnosis, therapeutics, and theranostics for lung cancer management has been discussed. Bioengineered, bioinspired, and biomimetic bio-nanotools of considerate translational value have been reviewed. Perspectives on existent oncostrategies, their critical comparison with bio-nanocarriers, and issues hampering their clinical bench side to bed transformation have also been summarized. [Image: see text]
Search related documents:
Co phrase search for related documents- adaptive innate and adjuvant therapy: 1, 2
- adaptive innate and administration route: 1, 2, 3, 4, 5, 6
- adaptive innate and low concentration: 1, 2
- adaptive innate and low molecular weight: 1, 2
- adaptive innate and low toxicity: 1
- adaptive innate and lung adenocarcinoma: 1
- adaptive innate and lung cancer: 1, 2, 3, 4, 5, 6, 7
- adaptive innate and lung cancer cell: 1
- adaptive innate and lung cancer cell metastasis: 1
- adaptive innate and lung cancer cell proliferation: 1
- adaptive innate and lung cancer diagnostic: 1
- adaptive innate and lung cancer prognosis: 1
- adaptive innate and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- adaptive innate and macrophage monocyte: 1, 2, 3, 4, 5
- adaptive innate and magnetic resonance: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date